The arrival of medical cannabis as a legal treatment option in the UK since November 2018 marked a turning point for patients with certain chronic and complex health conditions. However, despite the legalisation and increased public interest, there are many misconceptions about where medical cannabis fits in clinical care pathways. Is it a first-line treatment? Who can prescribe it? How accessible is it via the NHS compared to private providers like Releaf or Mamedica? This article offers an in-depth look at the status, limitations, and practicalities of accessing medical cannabis treatment today.
UK Legal Status and Regulatory Landscape for Medical Cannabis
The UK government legalised cannabis-based products for medicinal use in November 2018. This meant that healthcare professionals on the General Medical Council (GMC) Specialist Register could prescribe cannabis-derived products for medicinal use in humans (CBPMs). However, regulatory guidance from the National Institute for Health and Care Excellence (NICE) and NHS commissioning bodies remains cautious and selective, limiting routine access via the NHS.
Key points regarding the regulatory framework:
- Prescribing is restricted to consultant specialists with relevant expertise in conditions where traditional therapies have failed or are unsuitable. The treatment is intended as a last-resort option after conventional licensed drugs have been tried. There is tight clinical governance and monitoring due to the limited evidence base and evolving clinical experience.
Medical Cannabis: Not a First-Line Treatment
A crucial concept to understand is that medical cannabis is not considered a first-line treatment in the UK. This means that it does not replace established therapies such as antiepileptic drugs, painkillers, or disease-modifying agents for conditions where these are effective and appropriate.
Why is this the case?
Evidence Base: While there is promising research in certain areas like chronic neuropathic pain and refractory epilepsy, there is still a lack of large-scale clinical trial data that meet UK regulatory standards for widespread prescribing. Specialist Decision Making: All prescribing decisions must reflect an individual patient’s complex history and treatment response, typically overseen by specialists in neurology, pain management, or palliative care. Eligibility Criteria UK: Patients must meet strict eligibility criteria before a specialist will even consider cannabis products, including documented treatment failure with licensed medicines.Eligibility Criteria: What Patients Need to Know
Patients interested in medical cannabis should understand the typical eligibility framework used by specialists:
- Confirmed diagnosis of a qualifying condition (e.g., treatment-resistant epilepsy, multiple sclerosis spasticity, chronic neuropathic pain). Previous trials of licensed standard treatments with inadequate symptom control or intolerable side effects. Comprehensive medical records outlining past treatments and clinical evaluations. Ongoing specialist follow-up capacity to monitor treatment effectiveness and adverse events.
This selective approach safeguards patient safety and ensures that medical cannabis is introduced where conventional therapies have limited efficacy.
NHS Access vs Private Clinics: Reality Check
Although medical cannabis is legally prescribable on the NHS, in practice, NHS access remains very limited. There are just a handful of NHS consultants across the UK who have prescribed cannabis-based products publicly, and most NHS regions have no established pathways for routine access.
This barrier has resulted in many patients turning to private providers such as Releaf and Mamedica, who specialise in facilitating access through regulated routes. These companies use a specialist-led prescribing model:
- Remote (Online) Consultations: Patients can complete thorough medical questionnaires and have video consultations with GMC-registered consultants specialising in medical cannabis prescribing. In-Person Consultations: For those preferring or requiring face-to-face care, clinics provide expert assessments to confirm eligibility and suitability.
These private consultations ensure that decisions remain specialist-driven while improving geographic and scheduling accessibility. The process includes a comprehensive review of medical history, symptomatology, and previous treatments to align with eligibility criteria UK specialists require.
Why Do Patients Choose Private Over NHS?
- Speed of Access: Waiting times for NHS appointments with cannabis-prescribing consultants can be very long. Geographic Limitations: NHS specialists who prescribe medical cannabis are often concentrated in certain regions, requiring travel for patients. Continuity of Care: Private clinics often provide dedicated ongoing monitoring and dose adjustments.
It is important to note that private prescribing still follows the specialist-led regulated route mandated by UK law and cannot bypass clinical due diligence.
Remote Consultations: Increasing Accessibility
One of the most significant innovations in recent years is the use of online consultations for medical cannabis assessments. Both Releaf and Mamedica use secure digital platforms allowing patients to:
- Submit comprehensive medical histories via online questionnaires before the video call. Engage in detailed video consultations with specialists who can clarify symptoms and past treatments. Receive clear information on treatment expectations, side effects, and monitoring plans.
This approach reduces travel burdens, expands access across the UK, and supports faster specialist decision-making aligned with the eligibility criteria UK consultants require. While some patients will still need or prefer in-person consultations, remote options have democratized access without sacrificing the essential specialist oversight.
Common Mistakes When Researching Medical Cannabis
A frequent pitfall we see is patients encountering claims or content that omit critical details—especially regarding costs. To be clear:
- No prices were provided in the sources discussed here. The cost of private prescribing, products, and follow-up varies considerably. Patients should always request full transparent pricing from providers during consultation discussions.
Beware of marketing that glosses over the ongoing monitoring, follow-up appointments, and possible dose adjustments required. These are essential parts of the regulated treatment pathway, whether accessed via NHS or private routes.
Summary: Medical Cannabis Is a Specialist, Last-Resort Treatment Option
Aspect Key Facts Legal Status UK Legal since 2018 for specialist prescriptions; controlled via MHRA Prescribing Route Specialist-led only; eligibility based on failed conventional treatments Availability on NHS Very limited; few specialists prescribe; no standard referral pathway Private Access Via companies like Releaf and Mamedica offering online/in-person specialist consultations First-Line Status Not first-line; considered after other therapies exhausted or unsuitable Monitoring Essential ongoing specialist follow-up and clinical monitoring requiredWhat to Ask When Contacting Providers Like Releaf or Mamedica
- What specific eligibility criteria do you use to determine candidacy for medical cannabis? How does your specialist-led consultation process work—online, in-person, or both? What is included in follow-up care and monitoring after prescription? Can you provide transparent information about all costs involved (consultations, prescriptions, and products)? How is treatment effectiveness measured and side effects managed?
Final Thoughts
In the UK, medical cannabis remains a highly regulated, specialist-only treatment reserved for cases where conventional therapies have failed or are inappropriate. It is not prescribed as a first-line option, and patients must meet strict eligibility criteria overseen by consultants. NHS access is still in very early stages and quite limited, prompting many patients to seek specialist consultations through private providers like Releaf and Mamedica. Remote consultations now play a vital role in increasing accessibility while preserving the rigour of specialist decision making.
As interest grows, it is vital that patients approach medical cannabis with realistic expectations, seek advice from qualified specialists, and ensure they understand the ongoing commitment to monitoring and care that this treatment entails.
